| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.06 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.069 | 0.06 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.07 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.05 | 0.07 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.07 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | 0.064 | 0.07 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.055 | 0.07 |
| mRNA | Obatoclax Mesylate | GDSC1000 | pan-cancer | AAC | 0.062 | 0.07 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.07 |